Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOS172738 (Zeteletinib) in Advanced RET-Altered Solid Tumors
NCT03780517Phase 1Completed
- Sponsor
- Boston Pharmaceuticals
- Start
- Dec 2018
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label, single-arm trial of zeteletinib in solid tumor (advanced stage), non-small cell lung cancer (NSCLC) and Medullary Thyroid Cancer (MTC), sponsored by Boston Pharmaceuticals. Primary endpoints: Number of participants with any treatment-emergent serious adverse event at 3 months, Number of participants with any non-serious treatment-emergent adverse event at 3 months and 5 more. Started Dec 2018; status: completed.
02
Drugs
zeteletinib
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NCT03780517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03780517.